The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients

Clinical Endocrinology

Volumn 67, Issue 3, 2007, Pages 346-350

  Sahin, Mustafa ^a   Tanaci, Nedret ^a   Yucel, Muammer ^a   Tutuncu, Neslihan Bascil ^a   Guvener, Nilgun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ANTHROPOMETRY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; MEASUREMENT; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; INSULIN; LACTONES; MALE; MIDDLE AGED; OBESITY;

EID: 34548048768     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02888.x     Document Type: Article

References (16)

1. Davidson, M.H., Hauptman, J., DiGirolamo, M., Foreyt, J.P., Halsted, C.H., Heber, D., Heimburger, D.C., Lucas, C.P., Robbins, D.C., Chung, J. Heymsfield, S.B. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Journal of the American Medical Association, 281, 235 242. Erratum in: Journal of the American Medical Association 1999, 281: 1174.
2. Hollander, P.A., Elbein, S.C., Hirsch, I.B., Kelley, D., McGill, J., Taylor, T., Weiss, S.R., Crockett, S.E., Kaplan, R.A., Comstock, J., Lucas, C.P., Lodewick, P.A., Canovatchel, W., Chung, J. Hauptman, J. (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care, 21, 1288 1294.
3. Hanefeld, M. Sachse, G. (2002) The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism, 4, 415 423.
4. Pilichiewicz, A., O'Donovan, D., Feinle, C., Lei, Y., Wishart, J.M., Bryant, L., Meyer, J.H., Horowitz, M. Jones, K.L. (2003) Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 88, 3829 3834.
5. Damci, T., Yalin, S., Balci, H., Osar, Z., Korugan, U., Ozyazar, M. Ilkova, H. (2004) Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care, 27, 1077 1080.
6. O'Donovan, D., Horowitz, M., Russo, A., Feinle-Bisset, C., Murolo, N., Gentilcore, D., Wishart, J.M., Morris, H.A. Jones, K.L. (2004) Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia, 47, 2208 2214.
7. Schwizer, W., Asal, K., Kreiss, C., Mettraux, C., Borovicka, J., Remy, B., Guzelhan, C., Hartmann, D. Fried, M. (1997) Role of lipase in the regulation of upper gastrointestinal function in humans. American Journal of Physiology, 273, G612 G620.
8. Nauck, M.A., Bartels, E., Orskov, C., Ebert, R. Creutzfeldt, W. (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. Journal of Clinical Endocrinology and Metabolism, 76, 912 917.
9. Herrmann, C., Goke, R., Richter, G., Fehmann, H.C., Arnold, R. Goke, B. (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion, 56, 117 126.
10. Thomsen, C., Rasmussen, O., Lousen, T., Holst, J.J., Fenselau, S., Schrezenmeir, J. Hermansen, K. (1999) Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. American Journal of Clinical Nutrition, 69, 1135 1143.
11. Jayagopal, V., Kilpatrick, E.S., Jennings, P.E., Holding, S., Hepburn, D.A. Atkin, S.L. (2004) The biological variation of sex hormone-binding globulin in type 2 diabetes. Diabetes Care, 27, 278 280.
12. Nathan, D.M., Schreiber, E., Fogel, H., Mojsov, S. Habener, J.F. (1992) Insulinotropic action of glucagon like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care, 15, 270 276.
13. Matthews, J.N.S., Altman, D.G., Campbell, M.J. Royston, P. (1990) Analysis of serial measurements in medical research. British Medical Journal, 300, 230 235.
14. Deacon, C.F. (2005) What do we know about the secretion and degradation of incretin hormones? Regulatory Peptides, 128, 117 124.
15. O'Donovan, D., Feinle-Bisset, C., Wishart, J. Horowitz, M. (2003) Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. British Journal of Nutrition, 90, 849 852.
16. Rayner, C.K., Samsom, M., Jones, K.L. Horowitz, M. (2001) Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care, 24, 371 381.